COVID-19 Therapeutics

The COVID-19 Therapeutics program at the Vaccine and Immunotherapy Center (VIC) involves the development of medical countermeasures designed to treat active SARS-CoV-2 infections. Currently in the preclinical stage, these candidates are distinct from the center's vaccine initiatives, such as HaloVax. While the specific molecular modalities (e.g., monoclonal antibodies or small molecule inhibitors) and exact mechanisms of action have not been publicly detailed, the program focuses on neutralizing or inhibiting the SARS-CoV-2 virus to mitigate the severity of COVID-19. The research is part of VIC's broader infectious disease pipeline, which utilizes advanced immunology to develop rapid-response treatments for emerging pathogens.

Other names

COVID-19 TherapeuticCOVID19 TherapeuticCOVID 19 TherapeuticCOVID-19 TherapeuticsCOVID19 TherapeuticsCOVID 19 TherapeuticsVaccine and Immunotherapy Center COVID-19 therapeutic